BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals (TARS)Tarsus Pharmaceuticals2026-06-25 13:46 ESTPartnership

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people

Open original release

Related news

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Participate in Upcoming Investor Conference

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

View all latest news

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TARSZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

TARSZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

TARSBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

TARSGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

TARSMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
59.31 USD
Market cap
2.54B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States